Literature DB >> 15471372

An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis.

Richard H C Lazeron1, Serge A R B Rombouts, Philip Scheltens, Chris H Polman, Frederik Barkhof.   

Abstract

INTRODUCTION: Cognitive impairment occurs in a substantial number of multiple sclerosis (MS) patients and often includes frontal lobe dysfunction. We used functional magnetic resonance imaging (fMRI) to study planning, an executive function, in moderately impaired MS patients.
METHODS: An fMRI version of the Tower of London (ToL) test was used to study patterns of brain activation in 23 MS patients and 18 healthy controls. The median score on the Expanded Disability Status Scale (EDSS) for the MS patients was 4. fMRI data were analysed using whole brain random effects analysis as well as region of interest (ROI)-based methods to assess group effects. Within the MS group, associations with behavioural data and measures of disease severity (lesion load from structural MRI) were examined.
RESULTS: Test performance in MS patients was significantly worse than in controls. Group analysis for the MS patients and the controls showed for both groups globally the same areas of activation, located in the frontal and parietal lobes bilaterally and the cerebellum. Although visual inspection suggested a larger extent of activation in the MS group, no statistically significant differences between groups were found. In the ROI analysis, statistically significant larger extent of activation was only found in the cerebellum. No association between disease severity and brain activity could be determined in the MS group.
CONCLUSION: In MS patients with moderate disability and structural damage, the pattern and extent of brain activation during planning were maintained despite poorer performance. In contrast to other studies showing increased activity, the failure to do so in our group may reflect exhaustion of adaptive mechanisms.

Entities:  

Mesh:

Year:  2004        PMID: 15471372     DOI: 10.1191/1352458504ms1072oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  6 in total

1.  Enhancement of planning ability by transcranial direct current stimulation.

Authors:  Colleen A Dockery; Ruth Hueckel-Weng; Niels Birbaumer; Christian Plewnia
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

2.  miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis.

Authors:  Federica Scaroni; Caterina Visconte; Maria Serpente; Maria Teresa Golia; Martina Gabrielli; Marijn Huiskamp; Hanneke E Hulst; Tiziana Carandini; Milena De Riz; Anna Pietroboni; Emanuela Rotondo; Elio Scarpini; Daniela Galimberti; Charlotte E Teunissen; Maureen van Dam; Brigit A de Jong; Chiara Fenoglio; Claudia Verderio
Journal:  Cells       Date:  2022-05-05       Impact factor: 7.666

3.  A Meta-analysis on the neural basis of planning: Activation likelihood estimation of functional brain imaging results in the Tower of London task.

Authors:  Kai Nitschke; Lena Köstering; Lisa Finkel; Cornelius Weiller; Christoph P Kaller
Journal:  Hum Brain Mapp       Date:  2016-09-15       Impact factor: 5.038

Review 4.  Cognitive rehabilitation in multiple sclerosis: the role of plasticity.

Authors:  Nancy D Chiaravalloti; Helen M Genova; John DeLuca
Journal:  Front Neurol       Date:  2015-04-02       Impact factor: 4.003

5.  Identification of Cortical and Subcortical Correlates of Cognitive Performance in Multiple Sclerosis Using Voxel-Based Morphometry.

Authors:  Jordi A Matías-Guiu; Ana Cortés-Martínez; Paloma Montero; Vanesa Pytel; Teresa Moreno-Ramos; Manuela Jorquera; Miguel Yus; Juan Arrazola; Jorge Matías-Guiu
Journal:  Front Neurol       Date:  2018-10-29       Impact factor: 4.003

Review 6.  Treatment and management of cognitive dysfunction in patients with multiple sclerosis.

Authors:  John DeLuca; Nancy D Chiaravalloti; Brian M Sandroff
Journal:  Nat Rev Neurol       Date:  2020-05-05       Impact factor: 42.937

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.